See more : Jahwa Electronics. Co., Ltd (033240.KS) Income Statement Analysis – Financial Results
Complete financial analysis of MoonLake Immunotherapeutics (MLTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MoonLake Immunotherapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Goldenmax International Technology Ltd. (002636.SZ) Income Statement Analysis – Financial Results
- Celyad Oncology SA (CLYYF) Income Statement Analysis – Financial Results
- Zhongsheng Group Holdings Limited (ZSHGY) Income Statement Analysis – Financial Results
- Svenska Nyttobostäder AB (publ) (NYTTO-PREF.ST) Income Statement Analysis – Financial Results
- Ling Yui Holdings Limited (0784.HK) Income Statement Analysis – Financial Results
MoonLake Immunotherapeutics (MLTX)
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.16K | 12.36K | 4.97K | 0.00 |
| Gross Profit | -13.16K | -12.36K | -4.97K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.80M | 42.05M | 35.52M | 0.00 |
| General & Administrative | 22.32M | 23.01M | 21.66M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 18.03M | 0.00 |
| SG&A | 22.32M | 23.01M | 18.05M | 105.76K |
| Other Expenses | 0.00 | 591.73K | 0.00 | 0.00 |
| Operating Expenses | 54.12M | 65.06M | 53.57M | 105.76K |
| Cost & Expenses | 54.12M | 65.06M | 53.58M | 105.76K |
| Interest Income | 0.00 | 0.00 | 0.00 | 14.92K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 13.16K | 12.36K | 4.97K | 206.30K |
| EBITDA | -54.11M | -65.05M | -53.63M | -90.84K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -54.12M | -65.06M | -53.58M | -105.76K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.14M | 591.73K | 10.65M | 14.92K |
| Income Before Tax | -43.98M | -64.47M | -53.64M | -90.84K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 94.39K | 36.37K | 4.76K | -206.30K |
| Net Income | -36.01M | -64.51M | -53.64M | -90.84K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.73 | -2.20 | -6.84 | -0.01 |
| EPS Diluted | -0.73 | -2.20 | -6.84 | -0.01 |
| Weighted Avg Shares Out | 49.12M | 29.36M | 7.84M | 14.81M |
| Weighted Avg Shares Out (Dil) | 49.12M | 29.36M | 7.84M | 14.81M |
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital...
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is expected to reach $1 billion by 2029....
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion
MoonLake develops sonelokimab, targeting large markets like psoriasis and hidradenitis suppurativa, with promising Phase 2 data. Despite a competitive landscape with established IL-17 inhibitors, MoonLake's nanobody potentially offers better tissue penetration. Financially, MoonLake is secure with a cash runway for...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody ® sonelokimab in hidradenitis suppurativa (HS) and...
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
SAN FRANCISCO & ZUG, Switzerland--(BUSINESS WIRE)--MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory...
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
Source: https://incomestatements.info
Category: Stock Reports